Cancer vaccines composed of tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) are currently being clinically evaluated. To enhance the immunogenicity of GM-CSF-secreting tumor cell vaccines, a novel approach expressing GM-CSF as a membrane-bound form (mbGM-CSF) on the tumor cell surface was investigated. The intent was to enhance antigen presentation by increasing interactions between the tumor cell lines in the vaccine and GM-CSF receptor positive antigen presenting cells (APC), notably the patient's Langerhans cells residing within the intradermal injection site. B16.F10 cells engineered to express either membranebound or secreted GM-CSF were compared in the B16.F10 mouse melanoma model. We observed that mbGM-CSF on
Introduction
Use of tumor cells as vaccines to augment antitumor immunity has been extensively studied over the last several years both in preclinical tumor models and in clinical trials. 1, 2 One approach to improve the efficacy of tumor cell vaccines is the use of tumor cells genetically engineered to express and secrete cytokines. One effective cytokine in the induction of potent antitumor activity is granulocyte-macrophage colony-stimulating factor (GM-CSF). In preclinical and clinical studies, tumor cells secreting GM-CSF have stimulated antitumor responses. [3] [4] [5] [6] An allogeneic GM-CSF-secreting pancreatic cancer cell vaccine induced systemic dose-dependent immunity against autologous tumors as measured by increased post-vaccination delayed-type hypersensitivity (DTH) responses. 7 A common finding in the clinical results to date using these vaccines is that large doses of cancer cells and high levels of secreted GM-CSF have been required to observe the modest immune responses, and clinical improvements certainly leave room for improvement. Further improvements in terms of making the GM-CSF more efficient are clearly warranted.
A key characteristic of GM-CSF responsible for its effectiveness is its ability to stimulate immature dendritic cells (DCs), which are recognized as the most effective antigen presenting cells within the immune system. [8] [9] [10] A defined set of immature DCs referred to as Langerhans cells (LCs) resides in the epidermis. Once these LCs receive an appropriate stimulus (such as GM-CSF), they bind and engulf antigens and begin their maturation into fully differentiated dendritic cells, 11 that subsequently migrate with their processed antigens to lymph nodes where they stimulate HLA restricted conversion of naive T cells to cytotoxic T lymphocytes (CTLs). These antigenspecific CTLs can then help provide strong antitumor immunity. To date, a variety of immunotherapeutic approaches using dendritic cells have shown promising results and help to demonstrate DCs as a key component for induction of significant immune responses in cancer patients. 12 However, all these approaches require prior isolation of the DCs.
Approaches that could better utilize DCs in situ would be a major step forward in vaccine development. Our rationale for development of a novel melanoma cellbased vaccine focused on this premise of exploiting the host LCs located within the dermis. Such a strategy could avoid the long-term tissue culture and tedious manipulations currently needed to derive sufficient numbers of DC from each patient for therapy. 13 To maximize interaction of a tumor cell line vaccine with in situ LCs, we have transfected melanoma cell lines with a novel membranebound GM-CSF (mbGM-CSF) gene designed to enable GM-CSF expression as an integral protein on the tumor cell surface. We hypothesized that the high affinity binding of cell surface GM-CSF to its receptors on the LCs 14 in the skin would yield a strong direct interaction with the mbGM-CSF tumor cell vaccine. Such interactions are predicted to improve significantly the efficiency of HLArestricted antigen presentation and, thereby improve cellular immunity against the tumor.
We chose to evaluate our mbGM-CSF technology in the B16.F10 mouse melanoma model, a poorly immunogenic and highly lethal murine melanoma. Our results demonstrate that B16.F10 cells become highly immunogenic after genetic modification to express GM-CSF on their cell surface, and are capable of inducing strong systemic immunity that protects against and therapeutically treats implanted melanoma more effectively than vaccines containing only secreted GM-CSF. The data justify additional studies into the vaccine's mechanism of action and potentially clinical trials of tumor cell-based vaccines engineered to express mbGM-CSF on their surface.
Results

Generation of B16.F10 cell clones engineered to express GM-CSF as an intergral membrane-bound component or as the secreted form
B16.F10 cells were separately transfected with either the pmbGM-CSF plasmid (Figure 1 ) or the psecGM-CSF plasmid. Single cell clones of each were identified and expanded as described. Expression of membrane bound GM-CSF on transfected B16.F10 cells was analyzed by FACS using the GM-CSF specific MP1-22E9 mAb. As shown in Figure 2 , strong cell surface expression of GM-CSF was noted in the mbGM-CSF B16.F10 transfectant, designated as clone 2B10. This 2B10 clone is referred to as 'mbGM-CSF B16.F10'. As expected, both wild-type B16.F10 and the secGM-CSF transfectant clone sec20 were negative for cell-surface GM-CSF expression. The sec20 clone is referred to as 'secGM-CSF B16.F10'. Levels of GM-CSF secreted by each cell type were measured using a mouse GM-CSF ELISA. Wild-type B16.F10 cells did not secrete any measurable GM-CSF, secGM-CSF B16.F10 cell secreted GM-CSF at a level of 41 ng/10 6 cells/24 h, and mbGM-CSF B16.F10 released GM-CSF into the culture medium at a similar level of 50 ng/10 6 cells/24 h. Additional experiments were carried out to characterize the GM-CSF detected in the supernatants of mbGM-CSF B16.F10. Analysis of many single cell mbGM-CSF clones with differing mbGM-CSF content by FACS analysis demonstrated a direct correlation between mbGM-CSF expression and the level of GM-CSF in the supernatants of each clone. We were unable to find transfected clones with strong membrane-bound GM-CSF content that did not release a portion of the surface bound GM-CSF into the culture medium. Western blots documented that only mbGM-CSF molecules of the expected size were detectable in the cell lysates prepared from mbGM-CSF clones, indicating that only one form of GM-CSF was being synthesized (data not shown). There was no band on the Western blot corresponding to the molecular weight of conventional secreted GM-CSF run as control.
Gene Therapy
Cleavage of mbGM-CSF from the cell surface was also detected at low levels in vivo. In mice injected with 10 6 irradiated mbGM-CSF B16.F10 vaccine cells, 48 pg/ml of plasma GM-CSF was detected by ELISA at 4 h after intradermal injection. Levels then declined to 10 pg/ml at 24 h and became undetectable by 48 h (Figure 3 ). Similar measurements were made in mice injected with 10 6 irradiated B16.F10 cells secreting similar levels of GM-CSF. At 4 h, only 24 pg/ml plasma GM-CSF activity was detected, which by 24 h had declined to 5 pg/ml ( Figure  3 ). As expected, no GM-CSF was measured in plasma from mice injected with B16.F10 control cells. Importantly, at the same 4-h time-point, FACS analysis of mbGM-CSF B16.F10 cells recovered from the injection site demonstrated that a high level of the GM-CSF was still associated with the membrane (data not shown). Collectively, these data are consistent with a small percentage of the mbGM-CSF being cleaved from the tumor cell surface following administration, which is then rapidly cleared at rates equivalent to secreted GM-CSF.
Because many of the tumor animal experiments utilize transfected cells that are first irradiated to halt cell division, we verified that the 20 000 rads used to irradiate the vaccines did not alter the levels of either mbGM-CSF on the tumor cell surface or GM-CSF secreted (data not shown).
mbGM-CSF retains its biologic activity when present as an integral membrane component
For efficient presentation of antigen to LCs and subsequent activation of naive T cells, it is necessary for the mbGM-CSF to remain biologically active as an integral component of the tumor cell membrane. To investigate biologic activity of this mbGM-CSF, we evaluated whether the membrane-bound component was able to stimulate syngeneic bone marrow cells, cells which express the GM-CSF receptor and proliferate in the presence of soluble GM-CSF in a dose-dependent manner. 15 Cell membrane fractions isolated from each of the three types of B16.F10 tumor cells (wild type, mbGM-CSF, and secGM-CSF) were used in the bone marrow proliferation assay. We utilized membrane fractions from each of the three cell lines rather than intact cells to ensure that the GM-CSF activity measured was only from the mbGM-CSF that had been expressed as an integral membrane component. Results clearly showed that only the membrane fraction harvested from the mbGM-CSF B16.F10 was able to stimulate the proliferation of bone marrow cells. Membrane fractions from the control wild-type B16.F10 and sec GM-CSF B16.F10 showed no proliferation ( Figure 4 ). Bone marrow cell stimulation induced by the mbGM-CSF membrane fraction was specifically inhibited by addition of an anti-GM-CSF monoclonal antibody in a dose-dependent manner, in contrast to an isotype control antibody, which had no effect (data not shown). We also know from previous results that mbGM-CSF on the surface of intact cells is also active in this assay. These results demonstrate that membrane-bound GM-CSF on transfected B16.F10 melanoma cells retains its biologic activity. The GM-CSF detected by ELISA in supernatants of cultured mbGM-CSF B16.F10 cells was also active in the bone marrow stimulation assay (data not shown). This finding indicates that the mechanism responsible for releasing GM-CSF into the supernatant did not interfere with the functional domains of the GM-CSF molecule. Figure 5a , P Ͻ 0.01 between mbGM-CSF and secGM-CSF). These data establish that viable mbGM-CSF B16.F10 cells are significantly less tumorigeneic than either wild-type or secGM-CSF tumor cells. This significant decrease in the tumorigenicity of mbGM-CSFexpressing tumor cells was also observed when mice were injected intradermally rather than subcutaneously (data not shown).
To monitor and compare levels of systemic immunity that may have been induced by injection of the three types of viable tumor cells, all tumor-free animals from the experiment depicted in Figure 5 were re-challenged at day 41 with 10 5 live wild-type B16.F10 tumor cells. At 43 days after this rechallenge, all six mice in the mbGM-CSF group were still alive, and five of these six animals remained tumor-free. These results demonstrate that a systemic protective and durable immunity to wild-type tumor was induced in these animals by the prior administration of viable mbGM-CSF B16.F10 cells. In contrast, administration of B16.F10 wild-type cells to the two animals that remained tumor-free at day 41 in the original B16.F10 group quickly developed tumors and died of their tumor burden by day 35, implicating that no systemic immunity had been induced. Finally, both of the Gene Therapy two tumor-free animals from the original secGM-CSF group developed tumors, with one animal death.
Expression of mbGM-CSF on B16.F10 cell surface does not affect its in vitro growth rate or its growth in immune compromised mice
Because of the significant differences observed in in vivo growth rate among the three cell types ( Figure 5 ), in vitro growth experiments were carried out to test whether these differences were due to different intrinsic growth rates. In vitro growth rates of wild-type B16.F10 and the two GM-CSF transfected clones were essentially ident-ical, suggesting that the large differences seen in vivo were likely immune related. The ability of all three cell types to grow well in T cell-deficient Balb/c nu/nu nude mice further documented that immune responses were responsible for rejection of mbGM-CSF containing tumor cells and the subsequent rejection of live wild-type B16.F10 cells (data not shown).
Vaccination with irradiated mbGM-CSF B16.F10 yields protection from wild-type B16.F10 tumor challenge
The ability of mbGM-CSF B16.F10 cells to function as a protective vaccine was evaluated in the B16.F10 melanoma model by first vaccinating a group of 10 C57BL/6 mice with irradiated mbGM-CSF B16.F10 cells before a high dose challenge with live wild-type B16.F10 cells. A second group of 10 animals was vaccinated similarly with irradiated wild-type B16.F10 and a third group of 10 animals was included as a non-treated control. All vaccinations (10 6 cells/mouse) were administered intradermally into the left flank on day 1 and again 14 days later. All three groups of animals were then challenged 7 days later (21 days after first vaccination) with 10 5 live wild-type B16.F10 tumor cells by subcutaneous injection in the opposite flank. Results showed that animals vaccinated intradermally with 10 6 irradiated mbGM-CSF B16.F10 cells elicited a much stronger, protective antitumor response compared with the wild-type or control groups ( Figure 6 ). All mice in the wild-type B16.F10 vaccinated group developed palpable tumors in the first 2 weeks, and by day 35, 70% of the animals had died from their tumor burden. In contrast, animals vaccinated with the mbGM-CSF tumor cells were able to retard tumor growth significantly, resulting in death at day 35 of only 30% of the animals. Throughout the study, the group vaccinated with mbGM-CSF vaccine exhibited longer survival time (Figure 6a ), yielded more animals that remained tumor-free (Figure 6b ), and resulted in smaller tumors (Figure 6c ). Statistical analyses using Student's t test indicated that mice vaccinated with irradiated mbGM-CSF B16.F10 vaccine were more effectively protected from subsequently live tumor challenge as shown by increased survival (P = 0.003), delayed tumor growth (P = 0.005) and increased tumor-free animal numbers (P = 0.0002) between mbGM-CSF B16.F10 and parental B16.F10. Impressive levels of antitumor protection were also achieved when the tumor challenge was given by intravenous inoculation. In these experiments (data not shown), even though all 10 animals from the control group and six of 10 animals from the wild-type group had died by day 31, nine of 10 animals administered mbGM-CSF B16.F10 cells remained alive. At day 38, eight of these animals (80%) were still tumor-free.
Importantly, mbGM-CSF-vaccinated tumor-free survivors were resistant to a second tumor challenge given on day 127 for at least an additional 25 days, at which point they were killed for immunological analysis. Splenocytes from these surviving mice were compared with spleen cells from naive mice for cytotoxicity in a 51 Cr release assay. Results showed that the percentage of specific cell killing was significantly higher for spleen cells from treated survivors (39%) compared with naive spleen cells (7%). In addition, the production levels of the cytokines GM-CSF and IFN␥ in the culture media of spleen cells were compared after a 5-day stimulation with irradiated B16.F10 cells. IFN␥ was still produced at levels of 185 pg/10 6 cells/ml (naive control = 5 pg/10 6 cells/ml) and GM-CSF was produced at levels of 60 pg/10 6 cells/ml (naive control undetectable). The ability to still measure cytotoxicity and both GM-CSF and IFN␥ production demonstrates long-term immunity. (Figure 7) . By day 39, all 10 animals treated with irradiated wild-type B16.F10 cells had died. At this point in time, 70% of the animals given mbGM-CSF vaccine remained alive compared with 40% for animals given the secreted GM-CSF vaccine (Figure 7a ). Statistical analysis of the data showed a survival benefit in the mbGM-CSF vaccine group (log rank, P Ͻ 0.05). At all time-points, tumor size was also significantly smaller in the mbGM-CSF vaccine group compared with the secreted-GM-CSF group, with P value of 0.0012 ( Figure  7b ). 16 from the widely metastatic parental B16 cells as a cell line that preferentially metastasized to the lung. We therefore utilized this model to investigate the effect of mbGM-CSF vaccine on formation of B16.F10 lung metastases. We chose to evaluate lung metastases in a subgroup of the mice in the therapeutic protocol (Figure 7) , at a point in time where all animals from the wild-type treated group had died, yet the majority of mice treated with mbGM-CSF B16.F10 remained alive (day 39). Lungs were removed from the three mbGM-CSF mice expressing sizeable tumors, and evaluated histologically for the extent of metastases by staining serial sections with hematoxylin and eosin stains. Despite having fairly large primary tumors, lungs from the three mice treated with irradiated mbGM-CSF had no visible metastases ( Figure  8 ). In contrast, intensive lung metastases were observed in three B16.F10 wild-type controls animals that had recently died with similar sizes of primary tumor ( Figure  8a and b) . In addition, it was clearly evident that the lung architecture was markedly disrupted in B16.F10-treated mice compared with mbGM-CSF B16.F10-treated mice. Lungs from the mbGM-CSF B16.F10-treated animals closely resembled those from healthy naive animals.
The abilities of B16.F10, mbGM-CSF B16.F10 and secGM-CSF B16.F10 to inhibit the lung metastases was compared in a separate therapeutic study. Figure 9 presents the combined results for the extent of lung metastases observed in the three groups of mice from animals killed after 17 and 36 days. These data clearly demonstrate the superiority of the mbGM-CSF vaccine to retard growth of lung metastases. Figure 7 . On days 17 
Figure 8 Inhibition of B16.F10 lung metastases in mice treated with irradiated mbGM-CSF B16.F10 vaccine. Mice were injected and treated as described in Figure 7. On day 39, lungs of three mice in each group were collected, and evaluated for extent of metastases. (a) A view of lung morphology. Top three lungs were from the B16.F10 control group and the bottom three from the mbGM-CSF treated group. (b) Histological analysis of serial sections (hematoxylin and eosin stain). A ×4 view of the B16.F10 treated lung displays extensive lung metastases, in contrast to a ×4 view of mbGM-CSF-treated lung showing normal lung architecture.
Figure 9 Extent of B16.F10 lung metastases in mice treated with irradiated B16.F10, or mbGM-CSF B16.F10, or secGM-CSF B16.F10 vaccine. Mice were injected and treated as described in
Discussion
Data presented herein demonstrate that genetically engineering a novel membrane-bound (mb) form of GM-CSF on to the surface of B16 melanoma cells creates a potent vaccine that can induce strong systemic antitumor immune responses in C57BL/6 mice that are more effective than similar vaccines engineered to simply secrete the GM-CSF cytokine. We chose to investigate mbGM-CSF technology in the B16.F10 mouse melanoma model because this cell line has been documented by many to be a poorly immunogenic and highly lethal murine melanoma cell line, providing a reproducible, and stringent model for evaluating potential candidate vaccines. Our data show that B16.F10 becomes highly immunogenic after genetic modification to express cell-surface GM-CSF. Vaccination of C57BL/6 mice with B16.F10 tumor cells expressing membrane bound GM-CSF induced strong, systemic, antitumor immunity against itself, as well as against wild-type B16.F10 cells. These findings were seen in experiments utilizing viable cells as well as irradiated cells, and in both preventive and therapeutic protocols. In all three models, vaccines utilizing the mbGM-CSF B16F10 cells were consistently superior to vaccinations with either wild-type B16F10 cells or GM-CSF-secreting cells in eliciting systemic, long-lasting immunity capable of inhibiting tumor growth and increasing animal survival.
We initially reported that the mbGM-CSF vaccine had therapeutic effects in the P815 mastocytoma model. 17 In that publication, we emphasized that wild-type P815 cells by themselves are moderately immunogenic. Evidence for immune-based protection by mbGM-CSF vaccines in this model was an important first step. However, to establish this technology as an improved therapeutic option for clinical evaluation, mbGM-CSF tumor cell vaccines needed to be further studied in a highly malignant and non-immunogenic animal model. We therefore extended our studies into the B16 melanoma system, a highly lethal and poorly immunogenic tumor model. Showing superiority of the mbGM-CSF tumor vaccines in this very stringent melanoma model gives convincing evidence for the potential of this approach.
The mechanism through which tumor cells expressing mbGM-CSF are able to elicit superior antitumor effects is under active investigation. Our first objective was to establish that its mechanism of action was immunebased. Our finding that both transfected cell types grow at the same rate as parental wild-type cells in immune compromised Balb/c nude mice strongly implicate an immune basis for the superiority of the mbGM-CSF format as a vaccine. This implication is further substantiated by the results showing high levels of both INF-␥ and GM-CSF from spleen cells isolated from animals vaccinated with the mbGM-CSF vaccine and surviving challenge and re-challenge with viable wild-type tumor. Finally, the observation that rejection of live mbGM-CSF B16.F10 cells by non-immunized animals also induces a systemic protection from subsequent challenge with wild-type tumor conclusively establishes an immune-based mechanism.
Since immature DCs are known to express the receptor for GM-CSF, 14 our working hypothesis for the increased immune-based efficacy of mbGM-CSF tumor cell vaccine is focused on the membrane GM-CSF enabling a direct physical association between the tumor cells and the immature dendritic cells. This strong association should greatly enhance the initiation and the efficiency of antigen presentation. Our data are consistent with this mechanism. We showed that non-immunized, immune-competent mice were able to effectively reject viable mbGM-CSF cells, but could not prevent growth of cells expressing secreted GM-CSF. In addition, we showed that by simple HE staining, vaccines expressing mbGM-CSF lead to a significantly higher number of infiltrating cells into the site of injection at 24 h compared with vaccines secreting GM-CSF. These infiltrating cells were no longer at the site of injection by day 3. These data are indicative of more effective antigen presentation and a vigorous induction of immunity by mbGM-CSF cell vaccines. We are currently doing more detailed histology to characterize the infiltrating cells, which will include kinetics of their migration into, as well as their egress out of the injection site.
During our studies, it was observed that a portion of the membrane GM-CSF was released as biologically active material into the culture supernatants during in vitro culture. Data from a number of mbGM-CSF transfected clones showed that the level of GM-CSF activity in the supernatants directly correlated with the density of mbGM-CSF expression measured by FACS. The C-terminus of mouse GM-CSF protein has been reported to be highly accessible to protease cleavage. 18 Thus, we propose that GM-CSF activity released into the supernatants from B16.F10 mbGM-CSF clones results from proteolytic cleavage of a portion of membrane-bound GM-CSF. A small measurable amount of GM-CSF cleavage also occurs in vivo (Figure 3) . However, FACS analyses 4 h after injection of mbGM-CSF tumor cells shows that the majority of mbGM-CSF remains associated with the cell membrane.
We believe that the superiority of mbGM-CSF tumor cell vaccines is due to the inherent advantages provided by the membrane-bound form of the GM-CSF, and not simply dependent upon the amount of total GM-CSF produced. This question is pertinent because the mbGM-CSF constructs have both membrane-bound and secreted activity, as discussed above. Importantly, other studies have published that 10-fold higher levels of GM-CSF .F10 viable cells and treatments with 10-fold higher doses (10 7 cells) of irradiated GM-CSF-secreting tumor cells on days 3, 7, 10 and 14 were used. This protocol showed no significant antitumor activity in their syngeneic animal model and only 30% protection in their allogeneic model. The one exception that did show efficacy in the B16 melanoma model by using extremely high levels of secreted GM-CSF was the work by Dranoff et al, 3 who also utilized higher concentrations of irradiated tumor cells as the vaccine.
Injection of live mbGM-CSF B16F10 cells into normal immune competent mice not yet vaccinated are effectively rejected ( Figure 5 ). The mechanism of this rejection is likely due to a combination of the rapid induction of an immune response elicited to the modified tumor cells and an efficient engulfment and processing of injected mbGM-CSF tumor cells at the injection site. The later event would be key to preventing establishment of tumor growth. Consistent with this interpretation is the fact that no fatal toxicity was associated with inoculation of 10 5 or 10 6 live mbGM-CSF B16.F10 cells in our studies. This finding is in contrast to published observations by Dranoff et al, 3 in which he observed that profound leukocytosis, hepatosplenomegaly, and pulmonary hemorrhage were induced by injection of live GM-CSF-secreting B16.F10 cells. We are currently attempting to generate data directly verifying the more effective and rapid engulfment and presentation of these mbGM-CSF tumor cells by host antigen presenting cells.
We observed in the therapeutic model where tumors were established 4 days before treatment that the mbGM-CSF vaccines were effective at retarding lung metastases. Our analyses, though striking, were qualitative, since quantitation of this visually obvious difference was not feasible. As expected, there is inherent variation in the degree of metastatic cancer observed among animals when tumor cells are administered subcutaneously rather than by direct intravenous injection. If injected directly into the bloodstream, a more consistent and larger number of tumor cells are observed in lungs, and the metastases are largely distinct foci that can be readily quantitated. However, the mechanism that delivered these tumor cells to the lungs is not truly metastatic, but instead is largely by entrapment during circulation through the lung tissue. We chose to use the subcutaneous route of tumor cell administration to ensure any lung tumors were metastatic and not simply entrapped. The resulting higher animal to animal variation and characteristic areas of metastatic disease rather than distinct foci are why we used a qualitative system to 'score' the relative extent of lung metastases. These results visually stress an obvious difference in the appearance of the lungs, and show animals treated with mbGM-CSF vacGene Therapy cines are more similar to healthy lungs than to the metastatic lungs observed in animals treated with vaccines not containing mbGM-CSF.
Experiments aimed at defining the mechanism through which metastases are retarded are underway. We predict that the rapid and potent immunity elicited by the tumor cells with mbGM-CSF on their surfaces is a key factor in the mechanism responsible for this effect on lung metastases. In addition, the fact that the few mice treated with mbGM-CSF vaccine who did develop significant primary tumors still had no evidence of lung metastases is an important mechanistic clue to guide these studies.
In conclusion, our data provide strong evidence that systemic antitumor immunity can be elicited by vaccination with B16.F10 melanoma cells genetically modified to express GM-CSF on the cell surface. Results suggest that this novel membrane-bound GM-CSF vaccine could be a significant improvement over vaccines engineered to secrete GM-CSF. These data warrant further development and clinical testing of mbGM-CSF tumor cell vaccines. To this end, established human melanoma, glioma, and colorectal tumor cell lines have now been successfully engineered to express mbGM-CSF on their surface.
Materials and methods
Antibodies and plasmids Antibody MP1-22E9 (a monoclonal rat-anti-mouse GM-CSF antibody) and an isotype matched control antibody were purchased from Pharmingen (San Diego, CA, USA). Details on the construction of the membrane-bound GM-CSF plasmid vector (pmbGM-CSF) have been described previously. 17 Briefly, the 372 nucleotide cDNA of murine GM-CSF was obtained by PCR and cloned into the commercially available (Invitrogen, Carlsbad, CA, USA) pHOOK-1 plasmid just before the 5'-terminus of its PDGFR transmembrane domain. For comparison, a secretory GM-CSF plasmid (psecGM-CSF) was similarly constructed by introducing a stop codon before the PDGFR transmembrane domain. These two plasmids were subsequently transfected into B16.F10, from which single cell clones were isolated as described below.
Transfection of cells
Electroporation was used for transfecting the mbGM-CSF or secGM-CSF plasmid construct into B16.F10, a mouse B16 melanoma cell clone selected for its ability to metastasize to lung, as described previously. 17 Briefly, cells were grown in log phase using standard tissue culture methods in RPMI 1640 supplemented with 10% fetal bovine serum and antibiotics. Cells (5 × 10 6 cells, 0.5 ml) were electroporated at a voltage of 250 V in the presence of 50 g linearized plasmid vector. Cells were then incubated and selected with 800 g/ml G418 (Gibco BRL, Rockville, MD, USA). Single cell clones were subcloned by serial limiting dilution. Cell clones were screened by FACS for the presence of GM-CSF on their surface and by ELISA for the level of GM-CSF released into the culture medium (as described below).
Mice and cell lines
Both C57BL/6 female mice (8-10 weeks old) and Balb/c nu/nu mice were purchased from Charles Rivers Laboratories, Wilmington, MA, USA. The NIH Guidelines for the Care and Use of Laboratory Animals, and the Animal Welfare Act Public Law were followed throughout the entire study. B16.F10 murine melanoma cells 16 were maintained in RPMI 1640 supplemented with 10% heatinactivated fetal bovine serum and penicillin/ streptomycin. Clone 2B10 mbGM-CSF positive cells derived from B16.F10 transfected with the pmbGM-CSF vector and clone 20 secGM-CSF positive cells derived from B16.F10 transfected with the psecGM-CSF vector were maintained in the presence of 800 g/ml G418 (Gibco BRL). All cells were harvested with cell dissociation buffer (Gibco BRL) to limit proteolytic cleavage of mbGM-CSF molecules from the cell surface.
Flow cytometric analysis (FACS)
Samples of subconfluent cells containing 10 6 cells were pelleted and washed once with 2% fetal bovine serum in phosphate buffered saline (PBS). The cells were resuspended in 50 l wash buffer containing 40 g/ml ratanti-mouse GM-CSF antibody MP1-22E9 and incubated on ice for 30 min. Cells were washed twice with wash buffer, resuspended in wash buffer containing a fluorescein labelled secondary antibody (goat anti-rat, mouse absorbed; Southern Biotechnology Associates, Birmingham, AL, USA) at a concentration of 40 g/ml, and incubated on ice for 30 min. The cells were washed twice, and then resuspended in 500 l PBS. For particular experiments noted, cells were fixed with 4% paraformaldehyde in PBS. Flow cytometry analysis was carried out using a Beckton Dickinson FACSort (Becton Dickinson, San Jose, CA, USA).
ELISA specific for murine GM-CSF and IFN␥
The amount of mouse GM-CSF secreted by genetically engineered B16.F10 cells and the GM-CSF and IFN␥ from cultured splenocytes were each measured by commercially available quantitative ELISA tests following procedures provided by the manufacture (R&D Systems, Minneapolis, MN, USA).
Biologic activity of the mbGM-CSF expressed on the B16.F10 cells
Biologic activity of the mbGM-CSF engineered on to the surface of B16.F10 cells was measured by a bone marrow proliferation assay described previously, 15, 17 with a modification in sample preparation. Briefly, aliquots of the following cell lines containing 10 7 cells were harvested with cell dissociation buffer and pelleted: B16.F10, clone 2B10 (expressing mbGM-CSF) and clone sec20 (expressing secGM-CSF). Cell membrane fractions from all three cell types were collected by centrifugation at 2500 r.p.m. for 5 min after three cycles of freeze and thaw in the presence of 5 mM EDTA. Each membrane fraction was thoroughly resuspended in RPMI tissue culture medium and added to a round bottom well in the amounts indicated. C57BL/6 bone marrow cells (3 × 10 4 cells) were added to each well and the cultures were incubated 2 days at 37 o C in a 5% CO 2 humidified incubator. Wells were then pulsed overnight with 1 Ci of 3 H-thymidine per well and harvested the next day using a Cambridge Technology PHD Cell Harvester (Watertown, MA, USA) to determine the level of proliferation. , and viable secGM-CSF B16.F10 cells (sec20) in volumes of 50 l were each injected subcutaneously into the hind flanks of C57BL/6 mice (10 mice/group). Tumor cells were similarly injected subcutaneously into Balb/c nu/nu mice (five mice/group) to investigate the growth characteristics in immunedeficient animals. Tumor growth and animal survival were measured twice per week over the course of the experiments starting 7 to 10 days after the injections. Tumor sizes are expressed as a product of the longest diameter and the shortest diameter as measured by a calibrated micrometer. To investigate levels of systemic immunity developed by the live cell injections, the animals from all three groups that remained tumor-free at day 41 were challenged with viable B16.F10 wild-type cells (10 5 cells) and monitored again for tumor growth. Cobalt source. After irradiation, both groups of tumor cells were washed with PBS, resuspended at a concentration of 2 × 10 7 cells/ml, and either immediately used to vaccinate mice or frozen at Ϫ70 o C until use. Groups of 10 C57BL/6 mice were vaccinated intradermally into the hind flank with 10 6 of the designated irradiated vaccine cells. After 14 days, the mice were similarly boosted with the same number of the appropriate irradiated vaccine cells. Five days after the boost, mice were challenged subcutaneously (experiment 1) or intravenously (experiment 2) in the opposite flank with 10 5 live wildtype B16F10 cells. The concentration of B16.F10 wild-type cells used for challenging was predetermined by doseresponse experiments, and 10 5 cells were chosen as the dose which would result in death of essentially all control animals within 40 days. Tumor growth and animal survival were measured as described above.
CTL assays
Tumor animal experiments: comparisons of irradiated tumor vaccines in a therapeutic experimental protocol C57BL/6J mice were inoculated with 10 5 live B16.F10 tumor cells subcutaneously in the right flank. On day 4, groups of 10 mice were treated intradermally in the opposite flank with 1 × 10 6 irradiated cells of each of the three indicated vaccine compositions. Animals were similarly given second and third administrations of the designated vaccines on day 11 and day 18. Tumor formation and animal survival were then monitored as described above.
Lung histology
Animals were killed by cervical dislocation. Lungs were collected and fixed in cold 4% paraformadehyde. Specimens were processed and routine hematoxylin and eosin staining was carried out.
Statistical analysis
Tumor sizes were expressed as mean + s.e.m. The significant differences between groups were determined by paired two-tailed Student's t test. P values Ͻ0.05 were considered to be statistically significant.
